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Background: Systematic reviews and national guidelines conclude that the nebulised
route of administration of bronchodilators has no advantage over the use of a spacer in
moderately severe exacerbations of asthma. Whether this recommendation is implemen-
ted and whether it might affect use of staff time is unknown.
Objectives: To determine the current method of administration of bronchodilators to
those with non-life-threatening asthma attending emergency departments (ED) in London,
UK and to monitor the implementation of a new policy to administer bronchodilators by
spacers in one ED with a special reference to the time taken by nurses to administer the
therapy by two different routes.
Methods: Thirty-ﬁve EDs in Greater London were surveyed regarding their current
practice. A time and motion study was then undertaken in one department observing
nurses administering bronchodilators in the 3 weeks before and 3 weeks after a
departmental policy change to favour the use of spacer devices rather than nebulisers.
Results: The majority of EDs (94.3%) in Greater London were using the nebulised route of
administering bronchodilators to the majority of their adult patients. Spacers were more
commonly used for the treatment of children (60.3% of departments using spacers and
nebulisers or spacers alone). Over half of the hospitals surveyed (51.4%) were unaware that
the British Guidelines on Asthma Management suggested that outcomes were the same and
that there were potential advantages in the use of a spacer for both adults and children.
Time and motion studies showed that the use of a spacer took no more nursing time than
administration of the bronchodilator via a nebuliser; in fact treatment and set-up time
were considerably lower for spacers.
Conclusion: Spacer administration of bronchodilators to those with asthma attending EDs
utilises less treatment time than use of a nebuliser. A survey of EDs in Greater London has
shown that despite guideline conclusions there appears to be little evidence of reductionElsevier Ltd. All rights reserved.
846 7181; fax: +44 208 846 7999.
rial.ac.uk (M.R. Partridge).
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& 2008 Elsevier Ltd. All rights reserved.Background
In the UK, 5.2 million people have asthma. Over 76,000
adults and children were admitted to UK hospitals in 2005.1
Many more attend emergency departments (ED) with
exacerbations of asthma, which may present at varying
degrees of severity, and many of these are repetitive
attendees.2 Traditionally, the treatment for worsening
asthma is the administration of high-dose bronchodilators
and, depending on severity, a course of steroid tablets.
Several studies and a systematic review3 have suggested
that there is no advantage to the nebulised route compared
with multiple actuations from a standard metered dose
inhaler (MDI) activated through a spacer device. Reﬂecting
this, the British Guidelines on Asthma Management4,5 have
for some years highlighted the fact that in children metered
dose inhalers and spacers have advantages over nebulisers,
and more recently these guidelines6 have pointed out that
for adults there is similarly no evidence that nebulisers
are in any way preferable or more effective than bronch-
odilators administered via a spacer device. However,
personal observation suggests that nebulisers still seem
widely used, and when those using nebulisers were asked
informally why some commented that they thought the
use of spacers would be more time consuming. How widely
the new recommendations are implemented and potential
barriers and advantages associated with such a change
have not been studied in the UK. A study 16 years ago in
the US7 suggested potential cost-savings by substituting
nebulisers with MDIs and spacers, and suggested that the
amount of time spent administering treatment was reduced
by using MDIs and spacers and this was also less expensive,
especially when the patient was able to self-administer MDI
therapy.Methods
Survey
Thirty-ﬁve EDs in the Greater London region were contacted
by telephone and asked two questions regarding the current
practice for the treatment of acute asthma in both adults
and children in their departments. The researcher asked for
the specialist registrar (a middle-grade doctor in training to
become a specialist emergency physician) or the nurse in
charge. Details of the script for the telephone interview are
in Appendix, and all were asked if they were aware of the
changes that had been made in the British Asthma Guide-
lines and if they were using spacers in both adults and
children. If the ﬁrst contacted respondent was unable to
answer questions about children, the call was transferred to
the paediatric department.Time and motion study
In November 2006, the ED at Charing Cross Hospital London
implemented a new policy whereby bronchodilators would
be administered to those with severe but not life-threaten-
ing asthma, by spacer devices rather than via nebulisers. In
the 3 weeks prior to the implementation of this new policy
and in the 3 weeks after the policy change, nurses were
observed administering bronchodilators and the treatment
time recorded. Life-threatening cases were treated in the
traditional way with nebulisers, because trials of nebulisers
versus spacers have not been undertaken in this group
(Figure 1). This was a pragmatic observational study utilising
a time and motion observer being a science graduate who
observed nurses’ work in the ED. This was carried out at
different time slots throughout a 3-week period, before and
after the protocol change. During the initial 3-week period
20 patients were observed undergoing treatment, and
therefore the same number was observed post protocol
change.
Nebulisers were administered via aerosol generated from
wall oxygen supplies and all patients observed were adults.
Depending on the severity of the patients’ condition,
(classiﬁed using the British Asthma Guidelines),6 the
medication varied (Figure 1).
Nurses were observed using nebulisers and the total
treatment administration time was recorded, including total
nurse time from the time the nurse collected the medica-
tions to administration of the medication, further atten-
dances to observe the patient and completion of treatment
and dismantling of the equipment. All nurse interactions
with the patient were recorded. Observations were made by
the same observer using a stopwatch.
The department, implementation and audit of the
new policy
The Charing Cross ED is one of 35 in the greater London
region, and it serves a densely populated area in West
London. Within the department asthma is managed accord-
ing to the British Asthma Guidelines, and these are used for
teaching/training and are widely available within the
department on wall charts, etc. Respiratory nurse specialists
visit the department on a daily basis to obtain details of
patients who have attended and discharged to ensure
continuity of care. Stafﬁng levels were 5.4 consultants, 10
middle grade (specialist registrars) and 12 senior house
ofﬁcers (SHOs).
Implementation of the new policy was instituted follow-
ing full discussion and with the enthusiastic support of
the consultants working in the department and the
senior nurse manager and pharmacist. Talks regarding
the new policy were given to both nursing and medical
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PATIENT WITH ASTHMA?
(This protocol does not at present  apply to patients who are being treated for COPD)
Life threatening
• Peak expiratory flow (PEF) < 33% of best or 
predicted
• SpO2 < 92%
• Silent chest, cyanosis or feeble respiratory 
effort
• Bradycardia, dysrhythmia or hypotension
• Exhaustion, confusion or coma
Severe Asthma
• Peak expiratory flow (PEF) 33-50% of best or 
predicted
• Can’t complete sentences in one breath
• Respiratory rate ≥ 25 breaths/min
• Pulse ≥ 110 beats/min
Moderate Asthma
• Peak expiratory flow (PEF) > 50 – 75% of 
best or predicted
• Increasing symptoms
• No features of severe asthma
TREAT IN THE USUAL WAY 
WITH NEBULISED 
BRONCHODILATORS etc. 
(Trials of nebulisers versus spacers have not 
been undertaken in this group)
• 4 – 6 puffs Salbutamol from a metered dose 
inhaler via a spacer with the inhaler actuated by 
individual puffs into the spacer, with the patient 
taking a full breath after each actuation.
• This is followed by 4 puffs of Ipratropium
Bromide (20 micrograms) by single actuation 
followed by an individual deep breath. 
• Process repeated every 10 minutes until patient 
responds to treatment.
• 4 – 6 puffs Salbutamol alone from a 
metered dose inhaler via a spacer with the 
inhaler actuated by individual puffs into the 
spacer, with the patient taking a full breath 
after each actuation.
• Process repeated every 10 minutes until 
patient responds to treatment.
NOTE: Spacer should be left with patient after administration so that it is available for subsequent administrations  whether at 
home, or similarly on the wards, if admitted.
Patients on oxygen can be taken off oxygen for the few moments that it takes to administer the bronchodilator, but if there 
are any concerns about this, the patient should receive oxygen from nasal cannulae at a flow rate of four litres per minute, 
whilst the bronchodilator is administered.
Patients who are admitted: If the patient responds satisfactorily to initial therapy it is anticipated that bronchodilators will 
continue to be administered in the spacer rather than from a nebuliser after admission to the MAU or a ward. 
Background - Level One Evidence
From a Cochrane Systematic Review and meta-
analysis1 of 13 randomised controlled trials of 
MDIs and spacers versus nebuliser therapy for 
acute asthma. Admissions showed that MDI + 
spacers produced outcomes at least equivalent to 
nebulised therapy and suggested a trend toward 
fewer side effects and less time in the emergency 
department in childern.
1. Cates CJ. Holding chambers vs nebulisers for beta-agonist 
treatment of acute asthma.
CHANGES TO THE WAY IN WHICH WE ADMINISTER BRONCHODILATORS
Figure 1 A summary of the new protocol; classiﬁcations and indications for treatment.
Nebulisers or spacers for the administration of bronchodilators? 995staff and summary charts were widely distributed. Patient
information leaﬂets were made available to give to
patients who might previously have attended and been
given a nebuliser. The notes of patients with asthma
who attended the ED at the Charing Cross Hospital in
the 4 weeks following the policy change were audited
to assess whether they had been treated with bronchodila-
tors administered via a nebuliser or via a spacer, and
if by a nebuliser whether this was due to the patient having
life-threatening asthma for whom the new policy did not
apply.
For the audit, notes of relevant patients were identiﬁed
from the ED electronic register. Information regarding
diagnosis was recorded by several different methods;
either by patients’ complaint recorded by the receptionist,
or by the complaint as recorded by the triage nurse
(for example, shortness of breath, unwell, sore throat,
cough etc.), or by the ﬁnal diagnosis. Our audit of the
department register therefore included searches under all
of these categories so that a patient who attended and was
classiﬁed as a ‘‘viral illness’’ but was triaged as ‘‘short of
breath’’ and subsequently diagnosed with asthma would be
included in the audit. An attempt was then made to recover
all notes which had been scanned into the departmental
computer system concerning patients with these relevant
diagnoses.Costs
The materials used were costed by the hospital pharmacy
and the supplies department for disposable and medication
costs.
Results
Survey
All 35 Greater London hospital EDs that were contacted by
telephone responded to our questions. One asked for time to
think about the answers and two requested us to phone back
because the key member of the staff was currently busy with
an emergency.
Of the EDs surveyed, 33/35 (94.3%) conﬁrmed that in
adults nebulisers were used for the administration of
bronchodilators in non-life-threatening acute asthma, with
only 2/35 (5.7%) reporting that they used spacers. Thirty
departments (85.7%) commented separately on their treat-
ment of children and 11 of those (36.7%) used spacers
routinely, 10 (33.3%) used nebulisers routinely and nine out
of the 30 (30%) used both methods of administering
bronchodilators, apparently depending upon the clinical
situation.
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they were unaware that the current guidelines suggested
equivalent outcomes using spacers, but many did comment
that they knew that it was a good practice for children to be
treated by using spacers but they had not realised that this
practice also extended to adults. Seventeen departments
(48.6%) reported that they were aware of the guidelines’
recommendations but, nevertheless, 15 of these (88.2%)
continued to administer bronchodilators to the majority via
nebulisers and not by using spacers.Figure 3 The total time spent with the nurse was not
signiﬁcantly different between the nebuliser group with a
median time of 134.5 s (IQR: 95.5–178.25) compared to the
spacer group with a median of 155.5 s (IQR: 122.75–227.25).
However the set-up time was signiﬁcantly reduced with
nebulised patients taking a median time of 98.5 (IQR: 74–134)
compared to patient treated with a spacer of 23 (13.75–43.5).Time and motion study
Twenty patients were observed receiving treatment before
the protocol change and 20 patients in the 3 weeks
afterwards. These patients were selected by the researcher
operating similarly timed shifts during the 3 weeks pre- and
post-protocol change. The total treatment time using a
spacer was 123 s (median n ¼ 20, IQR 92.5–188.25), com-
pared with a total time using nebulisers of 1194 s (median,
n ¼ 20, IQR 806.75–1724.5, po0.001). This information is
summarised in Figure 2, and the total treatment time was
measured from when the nebuliser was switched on, or
when the ﬁrst puff was taken from the spacer, until the end
of the treatment in either case, and was clearly less using a
spacer. The total time that the nurse spent with the patient
during the two treatments was not signiﬁcantly different
(spacers 155.5 s [IQR 122.75–227.25] and nebulisers 134.5 s
[IQR: 95.5–178.25, p ¼ 0.38]). However, the set-up time was
signiﬁcantly reduced (spacers taking 23 s [IQR: 13.75–43.5],
nebulisers 98.5 s [IQR: 74–134], po0.001) (Figure 3).Figure 2 The total treatment time was reduced with spacers
compared to nebulisers with a median of 1194 s (IQR:
806.75–1724.5) compared to 123 s (IQR: 92.5–188.25).Audit
Audit of the notes of 58 patients (mean age 34.7 (SD 17.2
years) 23 male and 35 female)—who attended the depart-
ment with out-of-control asthma in the 4 weeks after the
protocol change—revealed that 25.9% of patients were
given nebulisers without clinical indication after the
protocol was introduced. Thirty (51.7%) of the patients
were treated appropriately either with a spacer or were
appropriately nebulised because they had a life-threatening
disease (four patients). Nine (15.5%) of the patients either
did not require treatment, were given inhalers alone (the
patients having requested an inhaler as their own had
ﬁnished), or treatment was only recorded as ‘‘salbutamol
given’’, i.e. it was not possible to determine the method of
administration.
Costs of implementation of the protocol
The costs of disposables and medication for each of these
methods based upon the departmental protocol and
expressed per single treatment and per 20 treatments are
shown in Table 1.
The total cost for one treatment with a nebuliser with
5mg salbutamol and 500mcg ipratropium was £1.11 [h1.63/
US$2.20] (excluding oxygen or air needed).
Total cost for one treatment using an MDI and spacer with
600mcg salbutamol and 80mcg ipratropium was £4.80
[h7.06/US$9.53].
Discussion
This study demonstrates that the nebulised route of
administering bronchodilators is still the dominant route
ARTICLE IN PRESS
Table 1 Summary of costs for nebulisers and spacers.
Nebuliser Spacer
Total cost for 1 treatment with 1 patient
Disposables ¼ £0.97 Disposables ¼ £4.70
Medication ¼ £0.14 Medication ¼ £0.10
Total ¼ £1.11 (Disposables include: Chamber £0.50,
Oxygen mask £0.35, Tubing £0.12)
Total ¼ £4.80 (Disposables include: AeroChamber £4.70)
Total cost for 10 treatments with 1 patient
Disposables ¼ £9.70 Disposables ¼ £4.70
Medication ¼ £1.40 Medication ¼ £1.00
Total ¼ £11.10 Total ¼ £5.70
Total cost for 20 treatments with 1 patient
Disposables ¼ £19.40 Disposables ¼ £4.70
Medication ¼ £2.80 Medication ¼ £2.00
Total ¼ £22.20 (h32.70/US$44.07) Total ¼ £6.70 (h10.01/US$13.50)
Table 1 provides a summary of the costs incurred for both methods of bronchodilator administration. The disposables used and the
different forms of the medications used in each mode are summarised, and demonstrate that over the course of 20 treatments the MDI
plus spacer is 70% less expensive than nebulisers. Only the AeroChamber was stocked following the change in policy as this is the only
spacer available in the UK, which ﬁts a variety of metered dose inhalers. It also takes up less room in a department than some other
large-volume spacers, which do not ﬁt all of the inhaler devices.
Nebulisers or spacers for the administration of bronchodilators? 997for the treatment of adults attending EDs with out-of-
control asthma in London, and whilst there has been a shift
towards the use of spacers in the treatment of children, this
is by no means complete. The reasons why the nebulised
route is still used is not known but it is likely to reﬂect a
long-term practice, and this study suggests a lack of
awareness of the evidence which suggests no beneﬁt from
this route of administration. We had suspected that a
perception of greater nurse time being necessary with use of
a spacer than with use of a nebuliser might represent one
reason for non-implementation of the guidelines recom-
mendation and for that reason undertook the time and
motion study. The methodology, whilst widely used, has
limitations in that the nurse knows that they are being
observed, but this would apply equally to observation of
both methods of administering the bronchodilator. In this
study the observer was not blinded to the purpose of the
study and this is similarly a potential source of error. It also
seems likely that the results could have been distorted in
part by a habit of leaving the patient ‘‘on the nebuliser’’
even when all solution has been aerosolised, which was
probably the explanation for one patient taking over 20min
to receive their bronchodilator. Despite these limitations, it
seems reasonable to conclude that we can reassure those
considering implementation of a new policy that it will not
involve nurses in a more time-consuming task.
The economic beneﬁts of the use of a spacer are harder to
discern. If the spacer were to be used to administer
salbutamol alone, a cheaper spacer than that used in this
study could be used. However, because patients with more
than mild asthma are treated with an anti-cholinergic agent
in addition to a beta-agonist, a spacer device which
accommodates both types of metered dose inhalers is
necessary and these tend to be more costly. If a patient
were to be given a single-patient-use spacer to receive asingle treatment in the casualty department it would
increase the expense, but for many patients using a
pressurised MDI a spacer represents an optimal way of them
also taking their preventative therapy and the patient can
thus be given the spacer for the administration of inhaled
steroids after their attendance in the ED. Similarly, those
admitted to hospital can retain the spacer used in the ED
when transferred to the ward. The policy regarding the
method of administering the bronchodilator thus does
however need to be consistent from the ED to the medical
admissions unit to the respiratory ward.
In 2005, 77,150 patients were admitted to the hospital in
the UK,1 and the median duration of admission in adults is 3
days (hospital episode data, 2005/2006). They are likely to
receive bronchodilators as a minimum of four times a day,
and over this time period with this therapeutic regimen the
costs of the spacer rapidly equal the use of a nebuliser or
indeed could lead to savings (Table 1).
Audit of compliance with the new policy in this study
suggested a number of breaches and others have suggested
that failure to implement guidelines often represents health
professionals not knowing of the content of the guidelines,
not believing the recommendation, doubting their ability to
deliver the recommendation or the health professional
making a change but then falling back into old habits.8
Reinforcing education and re-audit is likely to be necessary,
but further study may also be necessary to try and elucidate
further why new recommendations in this ﬁeld are not
implemented.Conﬂict of interest statement
None of the authors have any conﬂicts of interest related to
this study.
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Appendix. Telephone survey
These calls took place between 8.30 and 9.30 am during the
time course of the project.
Call script
‘‘Good morning, my name is Naomi Mason and I’m working
with Professor Partridge at Imperial College. We are doing a
survey of Emergency departments with regard to treatment
of acute asthma. I was wondering if I could speak to the
Registrar or the Nurse in Charge for one minute to ask a
couple of questions.(1) Firstly do you currently use nebulisers or spacers for
the treatment of non-life threatening acute asthma in
those attending your department and does the same
apply to adults as to children?(2a) If nebulisers are used:
Were you aware that the British Asthma Guidelines
have recommended that metered dose inhalers plus
spacers or nebulisers could be used for the treatmentof non-life threatening acute asthma, and that both
were equally effective? YES/NO(2b) If already using spacers:
When did you change your policy and is it implemen-
ted?
Many thanks for your time.’’Reference
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